| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SANTA CLARA, Calif.—Early September saw Agilent Technologies Inc. sign a definitive agreement with Mexican company ABC Instrumentación Analítica (ABCIA) to acquire assets of ABCIA. The privately held company, based in Mexico City, is a leading distributor of analytical solutions, including Agilent's own chemical analysis and life-science products.  
 
Financial details were not released, but as of press time for DDNews, the assumption was that the acquisition would be completed by Oct. 1, subject to customary closing conditions.  
 
ABCIA actually has a relationship with Agilent so longstanding that it goes back to before Agilent existed as an independent entity. The Mexican company was founded in 1986 as a distributor of Hewlett-Packard Co.'s analytical solutions, and ABCIA later became an Agilent distributor when HP spun off Agilent in 1999. ABCIA provides sales, application support and customer training for Agilent products, such as gas and liquid chromatographs, mass spectrometers, atomic and molecular spectroscopy systems and bioanalyzers.  
 
With a more than two-decade history of partnership behind them, notes Sylvia Escobar, vice president in charge of field operations for Agilent's chemical analysis business in the Americas, the post-acquisition situation will be one of a unified team that provides better customer service, more streamlined processes and more consistent delivery of top-tier services.
 
"The strategy is to improve the customer interface by providing a complete and well-integrated sales and service Agilent experience," Escobar tells DDNews. "The acquisition of ABCIA enables us to sell directly to customers and integrate processes with the existing Agilent service delivery organization. The direct channel enables Agilent to provide the Mexico customer base a richer experience and deeper relationships that will result in programs and solutions aligned with the business opportunities and technology needs of the Mexican market."  
 
"We have worked successfully with Agilent for many years, and see this acquisition as a natural fit for both parties," said César Espinoza, CEO and founder of ABCIA, in a news release announcing the deal. "We are pleased with the acquisition as it provides the opportunity to further enhance our long partnership with Agilent and solidify the brand's presence in the expanding Mexican market. The unification of our teams also provides our employees with a major opportunity for further professional development while ensuring that our clients will receive even better service."  
 
About 30 ABCIA employees are expected to transfer to Agilent at completion of the acquisition.   Looking toward the more far-reaching aims of the acquisition, Escobar says, "The long-term plans are to retain Agilent's market leadership position in chromatography and expand to new technologies such as NMR and spectroscopy. The focus of the channel will be directed at the growth opportunities in key markets, including energy and food safety testing."  
 

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue and orange double-helix representing DNA is undergoing transcription with a large orange shape representing RNA polymerase against a blue background

Harnessing CRISPR-Cas9: Knocking out genes in myeloid cells

Explore the applications of CRISPR-Cas9 technology in therapeutic development for Alzheimer’s disease.
A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue